Bacteriophage preparations and methods of use thereof
View Patent ↗Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of Clostridium species strains, in particular C. perfringens, C. septicum and C. difficile . In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens -specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens -specific bacteriophage. The invention also relates to the use of purified bacteriophage preparation in combination with antibiotics for the treatment of animals including poultry. The invention also relates to the use of the purified bacteriophage preparations as treatments effective against antibiotic-resistant strains of Clostridium.
1. A purified bacteriophage preparation for reducing mortality in poultry due to C. perfringens infections comprising four or more C. perfringens -specific bacteriophage selected from the group consisting of CPAS-7 accession number PTA-8478, CPAS-12 accession number PTA-8479, CPAS-15 accession number PTA-8480, CPAS-16 accession number PTA-8481 and CPLV-42 accession number PTA-8483, wherein each bacteriophage has lytic activity against at least 5 strains of a Clostridium species and a citrate-phosphate-thiosulfate buffer.
2. The purified bacteriophage preparation of claim 1 wherein the Clostridium species is Clostridium septicum.
3. The purified bacteriophage preparation of claim 1 wherein the Clostridium species is Clostridium difficile.
4. A purified bacteriophage preparation for reducing mortality in poultry due to C. perfringens infections comprising four or more C. perfringens -specific bacteriophage selected from the group consisting of CPAS-7 accession number PTA-8478, CPAS-12 accession number PTA-8479, CPAS-15 accession number PTA-8480, CPAS-16 accession number PTA-8481 and CPLV-42 accession number PTA-8483, wherein each bacteriophage has lytic activity against at least 5 strains of a Clostridium species which are antibiotic resistant and a citrate-phosphate-thiosulfate buffer.
5. A composition comprising purified bacteriophage preparation for reducing mortality in poultry due to C. perfringens infections comprising four or more C. perfringens -specific bacteriophage selected from the group consisting of CPAS-7 accession number PTA-8478, CPAS-12 accession number PTA-8479, CPAS-15 accession number PTA-8480, CPAS-16 accession number PTA-8481 and CPLV-42 accession number PTA-8483, wherein each bacteriophage has lytic activity against at least 5 strains of a Clostridium species and an antibiotic and a citrate-phosphate-thiosulfate buffer.
6. The composition of claim 5 wherein the antibiotic is bacitracin.
7. The composition of claim 6 wherein the antibiotic is chlortetracycline.
8. The purified bacteriophage preparation of claim 1 wherein the four or more C. perfringens -specific bacteriophage are CPAS-12 accession number PTA-8479, CPAS-15 accession number PTA-8480, CPAS-16 accession number PTA-8481 and CPLV-42 accession number PTA-8483.
9. The purified bacteriophage preparation of claim 1 wherein the four or more C. perfringens -specific bacteriophage are CPAS-7 accession number PTA-8478, CPAS-12 accession number PTA-8479, CPAS-15 accession number PTA-8480, CPAS-16 accession number PTA-8481 and CPLV-42 accession number PTA-8483.
10. The composition of claim 5 wherein the purified bacteriophage preparation comprises CPAS-12 accession number PTA-8479, CPAS-15 accession number PTA-8480, CPAS-16 accession number PTA-8481 and CPLV-42 accession number PTA-8483.
11. The composition of claim 5 wherein the purified bacteriophage preparation comprises CPAS-7 accession number PTA-8478, CPAS-12 accession number PTA-8479, CPAS-15 accession number PTA-8480, CPAS-16 accession number PTA-8481 and CPLV-42 accession number PTA-8483.